Rhythm Pharmaceuticals has crossed from an ultra-rare genetic-obesity franchise into a larger rare-disease commercial chapter. The March label expansion of IMCIVREE, the company's melanocortin-four receptor agonist, made it the first approved therapy for acquired hypothalamic obesity, a weight and hunger disorder that follows injury to the hypothalamus after tumors, surgery, or other insults. Management estimates roughly ten thousand people live with that condition in the United States, a population far larger than Bardet-Biedl syndrome and the monogenic POMC and leptin-receptor deficiencies that originally supported the product. The equity now prices a scale-up of that new indication, not merely persistence in the original genetic book.
Demand showed up immediately. More than four hundred patient start forms from about three hundred prescribers arrived between mid-March approval and the June close, after more than one hundred fifty forms in the first six weeks. Global product sales reached $71 million, up from $49 million a year earlier. United States sales of $51 million were seventy-two percent of the mix and rose thirty-eight percent sequentially as hypothalamic-obesity demand layered onto continued Bardet-Biedl growth. A French Contribution M rebate charge of nearly $4 million pulled international revenue backward even as reimbursed patient counts abroad kept rising. Selling costs jumped with the launch build, so the operating loss barely moved despite the sales step-up.
Cash and short-term investments of $331 million at mid-year still cover at least two years of the stated plan. Japan already granted marketing authorization in late August, converting a year-end regulatory milestone into a pricing-and-launch problem. The question the next several quarters answer is whether start forms convert into a reimbursed, persistent hypothalamic-obesity book large enough to support a high-teens sales multiple, and whether country launches in Japan and Europe extend that book before weekly and oral next-generation agonists have to carry the story.